EGF like and EMI domain containing 1, pseudogeneGenealiases: C3orf50 · NCRNA00259
Q-omics provides the consensus-scored EGFEM1P profile across patient tissues and cancer cell-line models. EGFEM1P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, EGFEM1P is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, EGFEM1P RNA expression shows 13,880 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, THCA, and TGCT as cancer lineages where EGFEM1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EGFEM1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EGFEM1P survival associations across molecular data types. EGFEM1P RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EGFEM1P RNA expression–survival associations across cancer types. High EGFEM1P expression shows unfavorable associations in KIRC and LIHC, but favorable associations in KIRP, THCA, UCS and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for EGFEM1P RNA expression.
This table summarizes EGFEM1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for EGFEM1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EGFEM1P shows lower tumor expression in BRCA, COAD and LUAD and higher tumor expression in THCA, LIHC and BLCA. The THCA box plot shows higher EGFEM1P RNA expression in tumor versus normal tissue (log2 FC = +0.983, t-test p < 0.001).
This table shows molecular features associated with EGFEM1P in patient tissues and cancer cell lines. In patient samples, EGFEM1P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
